
CNBC Excerpts: Pershing Square CEO Bill Ackman Speaks with CNBC's Andrew Ross Sorkin on 'Squawk Box' Today
WHEN: Today, Monday, May 5, 2025
WHERE: CNBC's "Squawk Box"
Following are excerpts from the unofficial transcript of a CNBC interview with Pershing Square CEO Bill Ackman on CNBC's "Squawk Box" (M-F, 6AM-9AM ET) today, Monday, May 5. Following are links to video on CNBC.com: https://www.cnbc.com/video/2025/05/05/bill-ackman-whats-important-is-that-tariffs-get-resolved-in-the-relative-short-term.html and https://www.cnbc.com/video/2025/05/05/pershing-square-ceo-bill-ackman-i-wouldnt-bet-against-berkshire-post-buffett.html.
All references must be sourced to CNBC.
ACKMAN ON BUFFETT
BILL ACKMAN: Buffett's been my, you know, one of my most important heroes, certainly in business and I would say in life.
ACKMAN ON HOWARD HUGHES
ACKMAN: What we do is we own all the land. We sell lots to homebuilders. Homebuilders build homes, people move in. And then the company over time builds the amenities, builds the community. I call it a bit like SimCity, but in real life. And eventually we build high rise office buildings and, you know, apartment buildings. And it's a great business, but it consumes a lot of capital because you have to keep building the cities. Now, the cities, at a certain point in time get to a level of maturity where they start actually throwing off cash. And that's really where we are with Howard Hughes today.
ACKMAN: Howard Hughes as a real estate company today is not going to throw off a lot of cash to your point, but five years from now, ten years from now, it's going to produce more cash that it can generate.
ACKMAN: Howard Hughes today couldn't afford to hire the 40 odd Pershing Square team members, the eight investment team members. So we're going to bring all the resources of Pershing Square to Howard Hughes, and we're going to charge a 15, we're going to get paid a $15 million fee, and we're going to get paid a incremental fee to the extent that the market cap of Howard Hughes grows at a rate in excess of inflation, we're going to get a 1.5% fee on the increase in market cap, basically above today's market cap. Let me finish for a second. And only if the market cap on a per share basis. So if we issue a bunch of stock to make an acquisition that doesn't increase our fees, it actually reduces the fees as a percentage.
ACKMAN ON LIKELIHOOD OF BUILDING INSURANCE COMPANY
ACKMAN: I think it's more likely that we will build an insurance company. In fact, we have a person that is a phenomenal executive in the industry that we're just beginning a conversation with that's intrigued by what we're doing. And I like the idea of building from scratch because you don't assume a bunch of other people's kind of liabilities. And I think, you know, he's a super talented executive and hopefully we can make a deal with him. But that would be a kind of more intrigued with the idea of building something from a blank sheet of paper.
ACKMAN ON BERKSHIRE HATHAWAY
ACKMAN: Greg Abel is known to be a superb operator and a very good allocator of capital, certainly in the businesses that he's managed. I think it's yet to be proven that the current management team has the, you know, capability that Buffett has had to obviously buy businesses and it's more challenging now because of the scale. So I don't I think for sure the businesses will be run arguably, you know, potentially even better than they've been run historically because now a great real operator focused on that running the company.
ACKMAN: I think they're going to start returning capital.
ANDREW ROSS SORKIN: You do? I think the form of dividends.
ACKMAN: I think they'll, yeah dividends. I think they will be a little bit more aggressive about buying back stock. I don't see Berkshire waking up in six months and Berkshire announcing $100 billion acquisition. I think the new CEO will be and the new board, not the new board, the current new CEO and the current board will be a little bit more careful on the first deals because if Berkshire's first deal turns out not to be a good one, you know, I think that the market will kind of frown upon that. But I think the business will do very well.
ACKMAN: I wouldn't bet against Berkshire.
ACKMAN ON INFLATION
ACKMAN: I think inflation is largely been wrung out of the economy. Right. Price of eggs. I think the price of energy is coming down and it's going to stay down. And I think, you know, obviously very, very good for the economy.
ACKMAN ON TARIFFS & THE FED
ACKMAN: I think tariffs if they were they ultimately get resolved will increase the cost of some by a percent of some products. But it's not like inflation that will compound. It's more like a one-time reset. And then we'll we won't have meaningful inflation from there. And I think that's a backdrop in which the Federal Reserve toward the end of the year, could start. It could have a few kind of rate cuts.
ACKMAN: I think a small cut relatively soon I think makes sense because I think what's happened is, you know, we've we've Q1's benefited by some frontloading of purchases and inventive tariffs. The uncertainty associated with, you know, Liberation Day, so to speak, is caused many businesses to pause and wait to see what's going to happen. And that's going to be reflected in Q2. And so I think you could, you know, there's definitely a deceleration in economy and, you know, now. Absolutely. So the question I think what's important is the tariffs get resolved in the relative short term because I do believe if we're still dealing with the tariff thing is still major headlines.
ACKMAN ON CHINA
ACKMAN: The right thing to do, in my view, is we pause on China. Let's give it a little more time. Maybe it's 180 days because we got we're going to be busy here. What that does is it stabilizes the risk to the US economy and small businesses around the country. But China is now highly incentivized to make a deal. Why? Because because of the shock of 145% of the potential for high tariffs against China, every company that's producing in China and selling to the US is moving their supply chains elsewhere.
ACKMAN ON HARVARD
ACKMAN: Harvard became, over time, a political advocacy organization for one party. When a university goes from being a university to a, you know, affecting, you know, becoming a political advocacy organization, it's not it doesn't deserve nonprofit status. I mean, and they have to Harvard should be a place where students go to learn and the best research gets done. It shouldn't be a place that is allowing pro-terrorist organizations on campus that only allows certain kinds of thinking and speech on campus. That's that's a political advocacy organization. It's not a university. So I don't think we're going to end up there where Harvard loses its tax-exempt status. I want Harvard to succeed. You know, it's been very important to me over time, but really, it got itself to a very bad place. And Alan Garber is a good president, but he's not managing. You know, the mismanagement here is Penny Pritzker. If this were any other kind of corporation, the notion that she's still chairman of Harvard, leading the charge here and in terms of how Harvard managed everything from COVID, I know we have to go, but it's an important topic to the endowment management, to waste, to free speech, to who they hired as president of the university. It's time for a change in leadership in the board at Harvard.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Palantir CEO Warns of AI Arms Race With China
Palantir (PLTR, Financials) CEO Alex Karp said Thursday that artificial intelligence poses serious risks and that the ongoing AI arms race will ultimately be won by either the United States or China. There are positive and negative consequences, and either we win or China will win, Karp told CNBC's Squawk on the Street. He emphasized that the U.S. currently holds an advantage due to corporate willingness to embrace new technologies, but said Western allies, particularly in Europe, are lagging behind and must learn from the U.S. approach. In the interview, Karp also addressed a recent New York Times report suggesting Palantir is assisting the Trump administration in gathering data on American citizens. He denied the claim, stating, We are not surveilling Americans. The Denver-based data analytics and AI software firm has gained 74% year to date as investors bet on the company's growing role in U.S. government contracts and defense applications. While the stock continues to outperform broader tech peers, Karp acknowledged investor concerns around its valuation. You don't like the price, exit, he said. This article first appeared on GuruFocus.
Yahoo
2 hours ago
- Yahoo
Palo Alto Networks, Inc. (PANW) Believes AI Robots Going Rogue Is Quite Difficult
We recently published a list of . In this article, we are going to take a look at where Palo Alto Networks, Inc. (NASDAQ:PANW) stands against other stocks that Jim Cramer discusses. Palo Alto Networks, Inc. (NASDAQ:PANW) is a cybersecurity company. The firm's shares have gained 8.9% year-to-date as it has managed to weather the storm that has hit the broader technology industry. Palo Alto Networks, Inc. (NASDAQ:PANW)'s sector, cybersecurity, has been a top Cramer pick in 2025. The CNBC host has praised these companies as he believes that not only do they stand to experience greater demand as firms seek to secure their AI systems, but also due to their non-existent exposure to trade frictions between the US and China. Here are his recent thoughts about Palo Alto Networks, Inc. (NASDAQ:PANW): 'Nitesh Arora came on the show from Palo Alto last week and said the Agentic, the ability to be able to get into Agentic, uh very difficult. That is something that George Kurtz thinks too. We don't wanna have our robots go rogue. Which is they wouldn't really go rogue, someone would make them go rogue.' Palo Alto Networks, Inc. (NASDAQ:PANW) recently reported its earnings. Cramer discussed the results in detail and commented: 'Okay so Palo Alto did not, you know they beat it, but they did not raise. Now there's a history of them doing that. I do think that this is an overreaction. I do think that, remember I said April was a tough month in this country. But this is the opportunity, now this is another one, this one usually goes down between seven and ten percent. Then it stabilizes tomorrow and by next week it starts going up. That's the pattern. And you know look I can just tell you that's a correct analysis or I can tell you that what happens every time. TJX, same thing. These companies do not put themselves in harm's way. They do not raise big because they know that that's going to lead to sadness. A cutting-edge computer lab full of IT experts monitoring the security of multiple systems. 'Yeah look I just think that it's business as usual there. It's AI. They have this, they are all in on AI and you have to be. And the threats are as horrible as ever. But at the same time, if you do not raise, the next quarter, especially when it's the end of your fiscal year, then your stock gets hit. That's the game. That's just the game. We know that.' Overall, PANW ranks 10th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of PANW as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. This article is originally published at . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline 83% of subjects maintained a clinically meaningful benefit with a 3 or more point improvement in Revised Venous Clinical Severity Score (rVCSS) 9.1 point average rVCSS improvement among the clinically meaningful benefit cohort Subjects experienced a median 74% improvement in leg pain Interim follow-up data indicate sustained improvements across all venous-specific quality-of-life (QoL) indicators A decision from the U.S. Food and Drug Administration (FDA) on the VenoValve is anticipated in the second half of 2025 Company to host live webcast with presenting Principal Investigator, today, June 6th at 11:20 AM ET / 10:20 AM CT - Access the Webcast Here IRVINE, CA / / June 6, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that interim two-year follow-up data on 42 subjects from the 75 person VenoValve U.S. pivotal trial will be presented today by lead enroller Dr. Cassius Iyad Ochoa Chaar, at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting (VAM25) being held June 4-7, 2025 in New Orleans, LA. Additionally, the Company announced it will host a live webcast to discuss these interim results today, Friday, June 6th at 11:20 AM ET / 10:20 AM CT (details below). Key interim two-year follow-up data being presented at VAM25 include: 83.3% of subjects (n=35/42) maintained a clinically meaningful benefit, defined as an improvement of 3 or more points in the revised Venous Clinical Severity Score (rVCSS). 9.1 point average rVCSS improvement among the responder cohort. A median 74% improvement in leg pain, as measured by the Visual Analog Scale (VAS). Wound healing outcomes in 17 subjects with 25 ulcers showed that 60% of ulcers healed completely, 24% decreased in size, and 16% increased in size. Patient-reported outcomes also demonstrated sustained improvements across all venous specific QoL indicators (VEINES-QoL/Sym). Among the subjects (n=30), a 100% valve patency rate. All values were calculated comparing each patient's baseline levels to the reported values at the patient's 24-month visit. The Revised Venous Clinical Severity Score (rVCSS) is a clinically validated scoring system used to track the progression or regression of venous diseases. "These interim two-year follow-up data demonstrate substantial and sustained improvement across all effectiveness endpoints at two years. This is extremely encouraging, especially when you consider that all the patients enrolled in the study had severe CVI and failed all other treatment options," said Robert Berman, enVVeno Medical's Chief Executive Officer. "Despite attempts over many decades, nobody has been able to create an effective treatment for severe CVI caused by malfunctioning valves in the deep veins of the leg. The VenoValve has the potential to change the treatment paradigm for deep venous CVI, both for the millions of patients suffering from severe CVI and the thousands of vascular surgeons who have been waiting for an effective treatment option." Dr. Cassius Iyad Ochoa Chaar, who is the Associate Professor of Surgery, Division of Vascular Surgery and Endovascular Therapy, Yale School of Medicine, will present the abstract titled, "Patients with Deep Venous Reflux Continue to Experience Clinical Improvement 2-year after Implantation of the VenoValve" today at VAM 2025. The VenoValve is a potential first-in-class, surgical replacement venous valve for patients with severe deep venous CVI. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA), with a decision anticipated in the second half of 2025. Webcast Details The Company will host a webcast presentation to discuss the results for investors, analysts and other interested parties today, June 6, 2025, at 11:20 AM ET / 10:20 AM CT. Joining enVVeno management for the event will be Dr. Chaar. The live webcast will be accessible on the Events page of the enVVeno website, and will be archived for 90 days. About CVI Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of $4 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. Cautionary Note on Forward-Looking Statements This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. INVESTOR CONTACT:Jenene Thomas, JTC Team, LLCNVNO@ 824-0775 MEDIA CONTACT:Glenn Silver, FINN 818-8198 SOURCE: enVVeno Medical Corporation View the original press release on ACCESS Newswire